ScinoPharm today announced that the company has completed construction of its Changshu plant on a 16-acre site. The facilities, located in Changshu, (Jiangsu province) China, include an R&D process development center and a multipurpose API (active pharmaceutical ingredients) manufacturing plant fully compliant with U.S., EU, and Chinese CGMP standards.
Roche and Prothena Corporation have entered into a worldwide collaboration to develop and...
When considering the purchase and implementation of single-use technologies there are many...
The Global Biological Standards Institute (GBSI) today presented findings from the first...
Merck has provided an update on the development program for MK-8931, a novel investigational oral β-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor.
Genmab A/S announced today it had reached an in vivo pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a [Eur]1.5 million payment (approximately DKK 11 million).
Alvotech today announced plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies. Alvotech’s current biosimilar assets include follow-on versions of leading monoclonal antibodies molecules, which will be brought to market by 2018.
Roche and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners’ DARPin ® biologics conjugated to toxic agents developed at Roche for the treatment of cancer.
The company reported that Novartis wants to use one of its injectable drug delivery systems with an experimental drug in early-stage testing. Unilife said it will supply Novartis with a customized drug delivery device that will allow the Novartis drug to be delivered to a targeted organ.
JHL Biotech, Inc., a provider of biopharmaceutical process development and manufacturing services, and Switzerland-based Selexis SA, a provider of technologies for mammalian cell line development, announced today that they have signed a non-exclusive strategic agreement to provide biopharmaceutical customers a seamless solution for the development and cGMP manufacturing of biologic drugs.
Zogenix, Inc. and Battelle have entered into a new long-term collaborative agreement regarding co-marketing of Zogenix's DosePro(R) needle-free drug delivery technology, advancing potential out-licensing opportunities for DosePro with biopharmaceutical clients, and expanding the application of the technology to higher-dose biologic therapies.
Who are the technical innovators in the US? The image we often have is that of the young Silicon Valley geek or the surfing California biopharma scientist -- sometimes brash and unafraid to challenge authority and champion new and better ideas.
New York officials say a $5.8 million grant and up to $6.2 million in tax credits have figured into Bausch & Lomb's decision to expand manufacturing and distribution in Rochester, N.Y. Gov. Andrew Cuomo says Valeant Pharmaceutical International will invest $106 million to expand capacity for its subsidiary's new line of contact lenses.
Merrimack Pharmaceuticals and Actavis have entered into a collaboration agreement in which Merrimack will utilize its proprietary nanoliposomal technology platform to develop and manufacture various pharmaceutical products for Actavis to commercialize around the world.
Genomic Health and ALMAC GROUP have announced that Genomic Health will exclusively license Almac Group's technology and intellectual property to further develop, validate and subsequently commercialize a multi-gene test to predict benefit from DNA damage-based chemotherapy drugs, such as the commonly used anthracycline-based regimens, in breast cancer.
Stratus Media Group, Inc., announced today the closing of its acquisition of two biopharmaceutical companies - Canterbury Laboratories, LLC, and Hygeia Therapeutics, Inc.
Pfizer announced today that it has entered into an agreement with GSK to explore the anti-cancer efficacy and the safety of GSK’s trametinib (GSK1120212) combined with Pfizer’s palbociclib (PD-0332991) in a Phase I/II study (Study 200344) in patients with advanced/metastatic melanoma.
Juan Ramón Alaix, CEO of Zoetis, on why he's bullish on animal health and how he built a mostly female executive team.
Biopharm GmbH, Heidelberg, announced today that they have signed an agreement with Merck to cooperate with Merck Serono, the biopharmaceutical division of Merck in their research activities directed toward the molecular engineering of a biologic compound for the treatment of osteoarthritis.
Growth in global prescription drug spending will slow to the lowest rate in decades as low-cost generic drugs continue replacing former blockbusters in the U.S. and Europe, where governments face new pressure to reduce health care spending, according to a new forecast.
Merck KGaA, Darmstadt, Germany, has announced an € 80 million investment in a new pharmaceutical manufacturing facility, to be located in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region (Yangtze River Delta area).
Merck announced Friday that it would cease active ingredient production at one of its plants in Puerto Rico in a blow to a city once considered a pharmaceutical hub. The company said production at a plant in the north coastal city of Barceloneta will end by late 2014 as part of a global restructuring.
Cell Therapeutics and Baxter International announced a partnership on Cell Therapeutics' drug pacritinib, a potential treatment for the bone marrow disease myelofibrosis. Cell Therapeutics said it could get as much as $172 million in payments from Baxter, and the companies will split the profits on U.S. sales if the drug is approved.
PixarBio’s founding team includes InVivo Therapeutics co-founders Frank Reynolds, and Robert S. Langer ScD, David H. Koch Institute Professor at the Massachusetts Institute of Technology, as well as polymer industry veteran Randy Holmes-Farley PhD and Katrin Holzhaus, an entrepreneur with a proven track record of success.
Eurofins Lancaster Labs and Celsis International to Provide Rapid Micro Validation and Screening ServicesNovember 18, 2013 8:02 am | News | Comments
Eurofins Lancaster Laboratories and Celsis International Ltd. announced today that they have entered into a collaboration through which Eurofins Lancaster Laboratories will provide contract rapid microbiology validation and screening services for the Celsis rapid detection technology platform.
The company said today it will spend $350 million to expand its insulin cartridge manufacturing in China, another $120 million for a similar improvement in France and $245 million to boost manufacturing capacity in Puerto Rico and Indianapolis.
The agreement will focus on the research, clinical development and commercialization of a number of new tumour-associated peptide (TUMAP)-based cancer vaccine candidates and other immunotherapies in oncology, targeting primarily gastric, prostate and non-small cell lung cancer.
A.P. Pharma, Inc. today reported it has initiated a program to expand its pipeline of sustained release products, including a new program targeting the relief of post-surgical pain. The company also announced it will pursue a post-approval expansion of its leading drug program for the treatment of chemotherapy-induced nausea and vomiting.
Thirty years ago, Congress passed the Orphan Drug Act as a way to lure pharmaceutical companies to develop drugs for rare diseases that had been "orphaned" — abandoned or ignored because they were unprofitable. The hope was that drugmakers would break even or post modest profits.
- Page 1